Non-antagonistic antibodies directed against the alpha chain of the IL7 receptor extracellular domain and use thereof in cancer treatment
US11230602B2 · kind B2 · utility
0Cited by
1References
28Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 28, 2017 |
| Grant date | Jan 25, 2022 |
| Priority date | — |
| Expiry date | Jul 17, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/03
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The description concerns humanized antibodies directed against the extracellular domain of the alpha chain of the receptor for interleukin-7 (IL-7), especially against the receptor for human IL-7 expressed on human cells (also designated human IL-7Ralpha or IL-7Ra or CD127) and which do not interfere with the IL-7 or TSLP signaling pathways. The antibodies described do not have an antagonistic effect on the IL-7 receptor, but may still present cytotoxic activity against CD127 positive cells. In a particular embodiment, the antibody does not have an agonist effect on the IL-7 receptor.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.